Form 10-Q Verrica Pharmaceuticals For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies
May 14, 2024 9:35 AM EDTJefferies analyst Glen Santangelo raised the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Updating model to reflect 1Q results. Overall, we remain encouraged with the launch and continue to see opportunity for... More
